.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Queensland Health
Cipla
AstraZeneca
Mallinckrodt
Baxter
QuintilesIMS
Fish and Richardson
Citi
Teva

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 064030

« Back to Dashboard
NDA 064030 describes ERYTHROMYCIN, which is a drug marketed by Paddock Llc, Perrigo Co, Akorn, Pharmafair, Fougera Pharms, Arbor Pharms Llc, Wockhardt, Alpharma Us Pharms, Renaissance Pharma, Mylan Pharms Inc, Lilly, Perrigo New York, Bausch And Lomb, Pharmaderm, Perrigo Co Tennessee, Teligent Pharma Inc, Elkins Sinn, Barr, Tolmar, Lyne, Ivax Sub Teva Pharms, Life Labs, G And W Labs Inc, Watson Labs, Parke Davis, Mylan, Ani Pharms Inc, Naska, Dista, Abraxis Pharm, Teva Parenteral, Baxter Hlthcare, Purepac Pharm, and Lederle, and is included in sixty NDAs. It is available from thirty-five suppliers. Additional details are available on the ERYTHROMYCIN profile page.

The generic ingredient in ERYTHROMYCIN is erythromycin stearate. There are ninety-nine drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the erythromycin stearate profile page.

Summary for 064030

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details

Pharmacology for NDA: 064030

Ingredient-typeMacrolides
Physiological EffectDecreased Sebaceous Gland Activity

Suppliers and Packaging for NDA: 064030

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ERYTHROMYCIN
erythromycin
OINTMENT;OPHTHALMIC 064030 ANDA Henry Schein Inc. 0404-7191 0404-7191-01 1 TUBE in 1 CARTON (0404-7191-01) > 3.5 g in 1 TUBE
ERYTHROMYCIN
erythromycin
OINTMENT;OPHTHALMIC 064030 ANDA MWI 13985-605 13985-605-03 1 TUBE in 1 CARTON (13985-605-03) > 3.5 g in 1 TUBE

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:OINTMENT;OPHTHALMICStrength0.5%
Approval Date:Jul 18, 1996TE:ATRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Accenture
QuintilesIMS
McKesson
Argus Health
McKinsey
Julphar
Chubb
Deloitte
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot